Settlement Overview
The U.S. Federal Trade Commission reached a settlement with CVS Health’s pharmacy‑benefit manager, Caremark, on 14 July 2026. The agreement obliges Caremark to limit its use of after‑market discounts, commonly referred to as rebates, and to count consumer purchases made through the TrumpRx website toward the deductibles required by certain health plans.
Key Provisions
Caremark must curtail rebate practices that have been criticized for inflating drug costs. Additionally, the settlement requires that payments made by patients on the TrumpRx platform be applied to health‑plan deductibles, but this provision will only become effective once the supporting regulations for the TrumpRx program are finalized. The settlement mirrors a prior FTC agreement with Cigna earlier in the year, which targeted similar rebate‑related practices.
Expected Impact
FTC Chairman Andrew Ferguson stated that the settlement is expected to generate billions of dollars in savings on drug prices for American consumers. He emphasized that the FTC, under the administration of President Donald Trump, will not tolerate anticompetitive behavior that raises prices.
TrumpRx Background
President Donald Trump launched the TrumpRx.gov platform in February 2026 to provide discounted generic and branded medications, with a particular focus on popular weight‑loss drugs from Eli Lilly (LLY) and Novo Nordisk (NVO). The service directs cash‑paying customers to the drugmakers’ websites for discounted products. Because TrumpRx operates outside of traditional insurance coverage, its usefulness is limited for consumers who must meet health‑plan deductibles before insurance benefits apply.
Contextual Note
The article was generated with AI assistance and reviewed by an editor, as indicated in the source footer.